Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 13/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891281 | 0.87 | GPR84 (0.49) | GPR84KMT2APARP1 | |
| SCHEMBL891178 | 0.85 | GPR84 (0.51) | GPR84KMT2AMEN1TP53CYP3A4 | |
| SCHEMBL891065 | 0.85 | GPR84 (0.51) | GPR84KMT2AMEN1TP53CYP3A4 | |
| SCHEMBL891164 | 0.85 | GPR84 (0.51) | GPR84KMT2AMEN1TP53CYP3A4 | |
| SCHEMBL891076 | 0.81 | DAO (0.44) | GPR84KMT2ATYR | |
| SCHEMBL1127503 | 0.71 | SIRT1 (0.39) | GPR84KMT2AMEN1MAPTHTT | |
| SCHEMBL11057529 | 0.70 | HIF1A (0.50) | GPR84KMT2AMEN1TP53CYP3A4 | |
| SCHEMBL9015231 | 0.70 | PTGS2 (0.35) | GPR84KMT2AMEN1TP53CYP3A4 | |
| SCHEMBL11040456 | 0.67 | KMT2A (0.32) | GPR84KMT2AMEN1TP53CYP3A4 | |
| SCHEMBL11300744 | 0.67 | KMT2A (0.33) | GPR84KMT2AHTR2AMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899298-B1 | DERIVATIVES OF 4,5-DIARYLPYRROLE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-08-18 | — | — | EP | disclosed |
| US-7618995-B2 | Derivatives of 4,5-diarylpyrrole, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2009-11-17 | — | — | US | disclosed |
| US-20080176924-A1 | antiinflammatory agents; cannabinoid receptor modulators; obesity; antagonists; N-((5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-methyl-1H-pyrrol-2-yl)methyl)-4-(trifluoromethyl)benzamide | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| EP-1899298-A2 | DERIVATIVES OF 4,5-DIARYLPYRROLE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007000505-A2 | DERIVATIVES OF 4,5-DIARYLPYRROLE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176924-A1 | antiinflammatory agents; cannabinoid receptor modulators; obesity; antagonists; N-((5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-methyl-1H-pyrrol-2-yl)methyl)-4-(trifluoromethyl)benzamide | CNR1, CNR2, GPR119 | GPR84 66/4885KMT2A 997/4885HTR2A 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.